Skip to main content
James Partyka, Pharmacist, Palm Springs, CA, H. Lee Moffitt Cancer Center and Research Institute

JamesSPartyka

Pharmacist Palm Springs, CA

Critical Care Pharmacy, Oncology Pharmacy, Pharmacotherapy

Executive Director

James S Partyka is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See James Partyka's full profile

Already have an account?

Summary

  • You will find I'm a multifaceted pharmaceutical professional and innovator with a proven record of successes spanning the Pharmaceutical, Biotechnology, Hospital and Academic Industries; with over 20 years immuno-oncology patient care, teaching, clinical research, and medical affairs experience; knowledge in writing clinical research and regulatory documents. I have a broad background in financial reporting with budget preparations, managing monthly and annual spend. I've been successful in trial management delivering high quality results within budget and I'm proficient in medical writing for protocols, informed consents, INDs, study reports, presentations and manuscripts.

    I was the Founding Director of the Clinical Trials Office and the Oncology Pharmacy Residency program at H. Lee Moffitt Cancer Center in Tampa, Florida.

    I am a Board Certified Pharmacotherapy Specialist (BCPS) and a Registered Pharmacist in the state of Florida.

    A few of my key accomplishments include:

    ★ Clinical Lead for the Marketing Authorization Application and the successful approval of Adcetris (brentuximab vedotin)

    ★ Founder of Pharmative, a Global Medical Communications Company for Patients, Scientists and Healthcare Professionals

    ★ Global Publication Lead for Nexavar (sorafenib)

    ★ Clinical research and / or product commercialization support for cabozantinib, CC-122, neratinib, brentuximab vedotin, TAK-441, sorafenib, motesanib, panitumumab, pegfilgrastim, filgrastim, darbepoetin alfa, palifermin, romiplostim, denosumab, and topotecan.

Hospital Affiliations

Education & Training

  • The University of Texas at Austin
    The University of Texas at AustinPharmD, 1989
  • University of Texas M.D. Anderson Cancer Center
    University of Texas M.D. Anderson Cancer CenterResidency
  • University of Connecticut
    University of ConnecticutBA/BS in Pharmacy

Awards, Honors, & Recognition

  • Employee of the Year Millenium, 2012

Professional Memberships

Publications & Presentations

Journal Articles

  • Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors  
    Goldman J, Partyka JS, Clinical Cancer Research, 3/2015
  • Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates  
    Perkins J, Partyka JS, Clinical Cancer Research, 12/2011